Business Context and Reporting Period
This Form 8-K filing by Atricure, Inc. (Atricure) reports a material definitive agreement entered into on October 4, 2018, with a report date of October 3, 2018. The filing details a public offering of common stock.
Key Financial Metrics
- Shares Offered: 2,500,000 shares of common stock.
- Public Offering Price: $30.75 per share.
- Underwriter Purchase Price: $28.905 per share.
- Expected Net Proceeds: Approximately $72.0 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 375,000 additional shares.
- Maximum Potential Proceeds: Approximately $82.8 million if the over-allotment option is exercised in full.
- Underwriters: J.P. Morgan Securities LLC and Piper Jaffray & Co.
Material Changes
The primary material change is the execution of an underwriting agreement for a new equity offering. This transaction is expected to significantly increase the company's cash liquidity upon closing, which is anticipated to occur on or about October 10, 2018. No prior period financial comparisons are provided in this specific filing as it reports a discrete event rather than periodic financial results.
Outlook, Risks, and Unusual Items
The offering is subject to customary closing conditions. The filing notes that the Underwriting Agreement contains standard representations, warranties, indemnification obligations, and termination provisions. The company has filed press releases regarding the proposed offering and its pricing as exhibits to this report. No specific risks or contingencies beyond standard underwriting terms are detailed in the text of this summary.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $72.0 million figure is an estimate.
- Confirm whether the underwriters exercise the 30-day option to purchase the additional 375,000 shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and termination rights.
- Check subsequent filings for the use of proceeds and any dilution impact on existing shareholders.